IBMX

Pan-specific inhibitor of phosphodiesterases (IC50=2-50 µM) [1]. Inhibition of PDEs leads to increased concentration of intracellular cAMP which activates PKA [2]. Does not inhibit PDE8 or PDE9 [3]. Weak adenosine receptor antagonist [4].

References:

1) Beavo et al. (1970), Effects of xanthine derivatives on lipolysis and on adenosine 3’,5’-monophosphate phosphodiesterase activity;  Mol. Pharmacol., 6 597

2) Tomes et al. (1993), Isobutylmethylxanthine and other classical cyclic nucleotide phosphodiesterase inhibitors affect cAMP-dependent protein kinase activity;  Cell Signal., 5 615

3) Soderling et al. (2000), Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions;  Curr. Opin. Cell Biol., 12 174

4) Daly et al. (1987), Adenosine receptors: development of selective agonists and antagonists;  Prog. Clin. Biol. Res., 230 41